.avif)
Revolution Medicines Email Format
Biotechnology Research
・
501-1,000 employees
・
Redwood City, CA, USA
Revolution Medicines is a clinical-stage biotechnology company focused on discovering and developing innovative targeted therapies for patients with RAS-addicted cancers.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@revmed.com
Company Overview
Industry
Biotechnology Research
Founded
2014
Headquarters
Redwood City, CA, USA
Revenue
$250M-$500M
FUNDING Stage
Public
Website
Key Executives
Mark A. Goldsmith (Chief Executive Officer and President), Jack Anders (Chief Financial Officer), Margaret (Peg) Horn (Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Revolution Medicines?
Revolution Medicines uses the firstinitiallast format, so Jane Smith would be jsmith@revmed.com.
What is Revolution Medicines' lead drug candidate in its RAS(ON) inhibitor pipeline?
Revolution Medicines' lead candidate is daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor being studied across five ongoing Phase 3 trials, including in metastatic pancreatic cancer and non-small cell lung cancer.
How many employees does Revolution Medicines have?
Revolution Medicines has approximately 1,042 employees. Tools like Clay can help you identify and verify specific contacts at the company for outreach or prospecting purposes.
Who is the CEO of Revolution Medicines?
Mark A. Goldsmith serves as Chief Executive Officer and President of Revolution Medicines. Jack Anders is the Chief Financial Officer, and Margaret (Peg) Horn holds the role of Chief Operating Officer.
Where is Revolution Medicines headquartered, and what types of cancers does it focus on?
Revolution Medicines is headquartered in Redwood City, CA, and focuses exclusively on RAS-addicted cancers, developing targeted RAS(ON) inhibitors for tumors driven by KRAS, NRAS, and HRAS mutations, including pancreatic and lung cancers.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating